We are live on ! Find out more
KNSA icon

Kiniksa Pharmaceuticals
KNSA

103 hedge funds and large institutions have $346M invested in Kiniksa Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 41 increasing their positions, 27 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more repeat investments, than reductions

Existing positions increased: 41 | Existing positions reduced: 27

31% more call options, than puts

Call options by funds: $3.67M | Put options by funds: $2.79M

10% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 20

2% more funds holding

Funds holding: 101 → 103 (+2)

5% more capital invested

Capital invested by funds: $330M → $346M (+$15.8M)

2.46% less ownership

Funds ownership: 89.31% → 86.85% (-2.5%)

Holders
103
Holders Change
+2
Holders Change %
+1.98%
% of All Funds
1.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
41
Reduced
27
Closed
20
Calls
$3.67M
Puts
$2.79M
Net Calls
+$874K
Net Calls Change
+$1.26M

Top Buyers

1
BlackRock
BlackRock
New York
+$4.47M
2
Renaissance Technologies
Renaissance Technologies
New York
+$3.73M
3
Millennium Management
Millennium Management
New York
+$3.69M
4
ECM
Endurant Capital Management
California
+$3M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$2.8M

Top Sellers

1
State Street
State Street
Massachusetts
-$6.99M
2
LPC
Lion Point Capital
New York
-$5.42M
3
OM
Opaleye Management
Massachusetts
-$3.5M
4
BC
Boxer Capital
California
-$3.31M
5
WP
Woodline Partners
California
-$2.67M
Name Holding Trade Value Shares
Change 		Change in
Stake
PAMS
1
Pictet Asset Management (Switzerland)
Switzerland
$41.8M +$2.63M +213,744 +6%
BlackRock
2
BlackRock
New York
$41M +$4.47M +363,530 +12%
HA
3
HHLR Advisors
Cayman Islands
$34.4M – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$34M +$2.8M +228,082 +9%
BBA
5
Baker Bros. Advisors
New York
$33M – – –
State Street
6
State Street
Massachusetts
$17.2M -$6.99M -568,911 -28%
ACH
7
ArrowMark Colorado Holdings
Colorado
$15M +$472K +38,399 +3%
Hudson Bay Capital Management
8
Hudson Bay Capital Management
Connecticut
$12.4M -$1.23M -100,000 -9%
OM
9
Opaleye Management
Massachusetts
$12.1M -$3.5M -285,000 -22%
RHJA
10
Rice Hall James & Associates
California
$8.39M -$302K -24,567 -3%
GIM
11
Granahan Investment Management
Massachusetts
$7.06M +$2.38M +193,688 +48%
Goldman Sachs
12
Goldman Sachs
New York
$6.82M +$1.1M +89,644 +18%
GPP
13
Great Point Partners
Connecticut
$6.32M +$697K +56,738 +12%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$6.28M +$698K +56,822 +12%
Millennium Management
15
Millennium Management
New York
$6.21M +$3.69M +300,288 +132%
Point72 Asset Management
16
Point72 Asset Management
Connecticut
$4.69M +$286K +23,252 +6%
Morgan Stanley
17
Morgan Stanley
New York
$4.2M +$1.25M +101,444 +40%
Renaissance Technologies
18
Renaissance Technologies
New York
$3.57M +$3.73M +303,300 New
Wellington Management Group
19
Wellington Management Group
Massachusetts
$3.54M -$1.26M -102,559 -25%
Northern Trust
20
Northern Trust
Illinois
$3.3M +$74.6K +6,074 +2%
ECM
21
Endurant Capital Management
California
$2.87M +$3M +244,125 New
Alyeska Investment Group
22
Alyeska Investment Group
Illinois
$2.81M -$307K -25,000 -9%
SCA
23
Spearhead Capital Advisors
Florida
$2.77M – – –
Fidelity Investments
24
Fidelity Investments
Massachusetts
$2.14M -$1.52M -123,400 -40%
Dimensional Fund Advisors
25
Dimensional Fund Advisors
Texas
$1.88M +$308K +25,031 +19%
1
2 3 4 5

KNSA Hedge Fund Activity: Q4 2021 in Review

103 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Kiniksa Pharmaceuticals (KNSA) for Q4 2021, worth a combined $346M — up 4.8% from $330M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new KNSA positions and 20 closed out — a net gain of 2 holders — while 41 added to existing stakes and 27 trimmed.

The largest buyer was BlackRock, adding an estimated $4.47M. The largest seller was State Street, cutting an estimated $6.99M.

  • 103 institutional investors held Kiniksa Pharmaceuticals (KNSA) as of Q4 2021, up from 101 in Q3 2021.
  • Funds reported $346M of Kiniksa Pharmaceuticals stock for Q4 2021, up 4.8% quarter-over-quarter.
  • 22 funds opened new Kiniksa Pharmaceuticals positions in Q4 2021 and 20 closed out, a net change of +2 holders.
  • The largest Kiniksa Pharmaceuticals buyer in Q4 2021 was BlackRock, an estimated $4.47M added.
  • The largest Kiniksa Pharmaceuticals seller in Q4 2021 was State Street, an estimated $6.99M sold.

Based on aggregated 13F filings for Q4 2021.